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Background: Scedosporium and Pseudallescheria species are the second most common lung-colonising fungi in cystic ﬁbrosis (CF) patients. For
epidemiological reasons it is important to trace sources of infection, routes of transmission and to determine whether these fungi are transient or
permanent colonisers of the respiratory tract. Molecular typing methods like multilocus sequence typing (MLST) help provide this data.
Methods: Clinical isolates of the P. boydii complex (including S. apiospermum and P. boydii) from CF patients in different regions of Germany
were studied using MLST. Five gene loci, ACT, CAL, RPB2, BT2 and SOD2, were analysed.
Results: The S. apiospermum isolates from 34 patients were assigned to 32 sequence types (STs), and the P. boydii isolates from 14 patients to
8 STs. The results revealed that patients can be colonised by individual strains for years.
Conclusions: The MLST scheme developed for S. apiospermum and P. boydii is a highly effective tool for epidemiologic studies worldwide. The
MLST data are accessible at http://mlst.mycologylab.org/.
© 2013 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Pseudallescheria boydii; Scedosporium apiospermum; Cystic ﬁbrosis; MLST; Genotyping1. Introduction
In CF patients, respiratory function becomes increasingly
affected by fungi during the course of the underlying disease.
Aspergillus fumigatus is the mould found most frequently and
is associated with allergic bronchopulmonary aspergillosis or
causes invasive mycosis, especially after organ transplantation.
Fungi of the Pseudallescheria/Scedosporium complex rank
second among colonising hyphomycetes [2–4]. This complex☆ These results have been presented in abstract form at the Second Meeting of
the ECMM/ISHAM Working Group on Fungal respiratory infections in Cystic
Fibrosis (Fri-CF), Angers (France), September 1–2, 2011 [1].
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http://dx.doi.org/10.1016/j.jcf.2013.05.007includes Scedosporium apiospermum, Pseudallescheria boydii,
Scedosporium aurantiacum, Pseudallescheria minutispora,
Scedosporium dehoogii and the distinct species Scedosporium
prolificans. The percentages of the respective isolates from CF
patients sent to the reference laboratory at the Robert Koch-
Institute (RKI) between 1995 and 2010 were 49.4%, 23.5%,
9.4%, 2.4% and 15.3%. S. dehoogii was not found in clinical
samples at all. This complex of hyphomycetes is of special
importance because of diagnostic difficulties and a higher
resistance to antifungal agents compared to A. fumigatus. How
patients acquire these fungi is still unclear, especially because
Scedosporium species are hardly ever detected in indoor air but
are commonly found in polluted water and soil [5–7]. Some
authors reported that CF patients can be chronically colonised
by S. apiospermum [8–10]. Nevertheless, the following issuesby Elsevier B.V. All rights reserved.
Table 1
List of P. boydii isolates showing the allele types of ITS and the five MLST loci and sequence types (STs).
23 41 m delF508/delF508 K (BY) 2009/03 Sputum 09-0355.01 P1 P2 P3 P3 P4 P5 #P7
20 16 f Unknown B (BE) 2009/01 Throat swab 09-0038.01 P1 P2 P3 P3 P4 P5 #P7
B (BE) 2009/06 Sputum 09-0443.01 P1 P2 P3 P3 P4 P5 #P7
46 18 f delF508/c.1521–1523delCTT Q (RP) 2010/07* Sputum 10-0455.01 P1 P3 P4 P4 P5 P6 #P8
Q (RP) 2010/07* Sputum 10-0455.02 P1 P3 P4 P4 P5 P6 #P8
CBS 418.73 n.d. n.d. None n.d. n.d. Soil (Tadzhikistan) – P1 P2 P3 P3 P3 P5 #P6
CBS 101.22T n.d. n.d. None n.d. n.d. Mycetoma (USA) – P1 P4 P5 P2 P2 P4 #P9
P2 P1 P1 P1 P1 P1
P2 P1 P1 P1 P1 P1
P2 P1 P1 P1 P1 P1
P2 P1 P1 P1 P1 P1
P2 P1 P1 P1 P1 P1
P2 P1 P1 P1 P1 P1
P2 P1 P1 P1 P1 P1
P2 P1 P1 P1 P1 P1
P2 P1 P1 P1 P1 P1
P2 P1 P1 P1 P1 P1
P2 P1 P1 P1 P1 P1
P2 P1 P1 P1 P1 P1
P2 P1 P1 P1 P1 P1
P2 P1 P1 P1 P1 P1
P2 P1 P1 P1 P1 P1
P2 P1 P1 P1 P1 P1
P1 P2 P3 P3 P3 P5
P2 P1 P1 P1 P1 P1
P1 P2 P3 P3 P3 P5
P2 P1 P1 P1 P1 P1
P1 P1 P1 P1 P1 P2
P1 P1 P1 P1 P1 P2
P1 P1 P1 P1 P1 P2
P1 P1 P1 P1 P1 P2
P1 P1 P1 P1 P1 P2
P1 P1 P1 P1 P1 P2
P3 P1 P2 P2 P2 P3
P3 P1 P2 P2 P2 P3
P3 P1 P2 P2 P2 P3
P3 P1 P2 P2 P2 P3
P3 P1 P2 P2 P2 P3
P3 P1 P2 P2 P2 P3
P3 P1 P2 P2 P2 P3
P3 P1 P2 P2 P2 P3
P3 P1 P2 P2 P2 P3
P3 P1 P2 P2 P2 P3
P3 P1 P2 P2 P2 P3
P1 P1 P2 P2 P2 P4
P1 P1 P2 P4 P2 P4
P1 P2 P3 P3 P4 P5
P1 P2 P3 P3 P4 P5
P1 P2 P3 P3 P4 P5
Patient no.
Age§
[y]
Sex CFTR  genotype
CF center
(federal
state)
Isolation 
year/month
RKI no. ITS ACT CAL RPB2 BT2 SOD2 ST
6 30 n.a. Unknown O (NW) 2001/07 01-0715.01 #P1
47 26 f delF508/delF508 M (NW) 2010/09 10-0570.01 #P1
M (NW) 2010/09* 10-0616.01 #P1
M (NW) 2010/09* 10-0616.02 #P1
38 4 m delF508/– P (HH) 2010/01* 10-0143.01 #P1
P (HH) 2010/01* 10-0143.02 #P1
P (HH) 2010/01* 10-0144.01 #P1
P (HH) 2010/05~ 10-0343.01 #P1
P (HH) 2010/05~ 10-0344.01 #P1
P (HH) 2010/05~ 10-0345.01 #P1
37 16 f delF508/– P (HH) 2010/01* 10-0135.01 #P1
P (HH) 2010/01* 10-0136.01 #P1
P (HH) 2010/02~ 10-0137.01 #P1
P (HH) 2010/02~ 10-0138.01 #P1
P (HH) 2010/03 10-0140.01 #P1
10 15 m delF508/delF508 K (BY) 2001/12 02-0167.01 #P1
K (BY) 2002/01 02-0188.01 #P6
K (BY) 2002/02 02-0363.01 #P1
K (BY) 2009/02
Source
Sputum
n.d.
Sputum
Sputum
Throat swab
Throat swab
Throat swab
Sputum
Sputum
Sputum
Sputum
Sputum
Sputum
Sputum
Throat swab
Sputum
Sputum
n.d.
Sputum
K (BY) 2009/07 Sputum
09-0160.01 #P6
09-0504.01 #P1
5 36 f delF508/delF508 K (BY) 2001/07* Sputum 01-0710.01 #P2
K (BY) 2001/07* Sputum 01-0711.01 #P2
K (BY) 2001/08 Sputum 01-0719.01 #P2
K (BY) 2001/09 Sputum 01-0830.01 #P2
K (BY) 2009/12 Sputum 09-0822.01 #P2
K (BY) 2010/02 Sputum 10-0165.01 #P2
35 20 m delF508/delF508 F (LS) 2010/01 Sputum 10-0049.01 #P3
F (LS) 2010/04 Sputum 10-0254.01 #P3
F (LS) 2010/09 Sputum 10-0594.01 #P3
13 14 m delF508/delF508 F (LS) 2007/07 n.d. 07-0385.01 #P3
F (LS) 2009/03 Sputum 09-0257.01 #P3
F (LS) 2009/07 Sputum 09-0563.01 #P3
F (LS) 2009/08 Sputum 09-0573.01 #P3
F (LS) 2009/10 Sputum 09-0730.01 #P3
F (LS) 2009/11 Palatine tonsil swab 09-0768.01 #P3
F (LS) 2010/02 Sputum 10-0180.01 #P3
F (LS) 2010/03 Sputum 10-0238.01 #P3
1 26 m c.1007T>A/– B (BE) 1995/08 Sputum 95-2499.01 #P4
2 16 f delF508/R553X N (BB) 1998/11 Sputum 98-0503.01 #P5
36 19 f delF508/delF508 F (LS) 2010/01 Sputum 10-0129.01 #P7
F (LS) 2010/04* Sputum 10-0314.01 #P7
F (LS) 2010/04* Sputum 10-0315.01 #P7
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594 A. Bernhardt et al. / Journal of Cystic Fibrosis 12 (2013) 592–598are as yet unclear: (i) the clinical relevance, (ii) whether patients
are colonised by one or more strains, and (iii) the effect of
antimycotic treatment on the colonisation with these pathogens.
For epidemiological studies it is necessary to exactly identify
strains on a subspecies level. MLST has been proven to give
highly reproducible genotyping results that are comparable
worldwide [11–14]. Therefore we decided to use MLST in
studying S. apiospermum and P. boydii as the most frequently
isolated species in the CF context within the S. apiospermum
species complex in Germany.
2. Materials and methods
2.1. Fungal isolates
Clinical samples from the respiratory tract of CF patients were
cultivated at CF centres from geographically diverse locations in
Germany. Phenotypically distinct isolates preliminarily identified
as Pseudallescheria or Scedosporium species were sent to the
reference laboratory. Re-identification was performed by se-
quencing of the internal transcribed spacer (ITS) region of the
rDNA [15]. The study included all S. apiospermum and P. boydii
isolates received continuously between 2009 and 2010. The
number of isolates was increased by including previous isolates
from these patients and other previously archived CF isolates,
amounting to a total of 115. Forty-seven isolates from 14
patients were identified as P. boydii (Table 1) and 68 isolates
from 34 patients as S. apiospermum (Table 2). Patients were
between 4 and 41 years of age at the time of the first isolation of
the fungus, as documented at the CF centre currently treating
the patient; on average, females were 18.9 years old and males
21.3. There was no significant difference between patients with
a homozygote and heterozygote mutation of the cystic fibrosis
transmembrane conductance regulator (CFTR) gene and the
mean age at the time of the first isolation of the S. apiospermum
species complex.
Two reference strains for P. boydii (CBS 101.22T and CBS
418.73) and three reference strains for S. apiospermum (CBS
100392, CBS 100395 and CBS 117407T) were included in the
study.
The isolates were stored at −70 °C in Microbank™ tubes
(Pro-Lab Diagnostics, Bromborough, UK). Before DNA extrac-
tion the isolates were grown on potato dextrose agar (PDA) for
seven days at 37 °C.
2.2. DNA extraction
DNA extraction and purification were performed with the
FFPE Tissue LEV DNA purification kit designed for the
Maxwell® 16 Instrument (Promega, Mannheim, Germany) with
minor modification of the manufacturer's protocol. DNA was
purified directly from fungal cultures. An inoculating loop ofNotes to Table 1:
n.d.— no data; § — age at the date of ﬁrst isolation of Scedosporium ssp.; m — ma
⁎ and ~—multiple isolates from the same sample; BY— Bavaria; BE— Berlin; BB
Westphalia; RP — Rhineland-Palatinate; and CBS — Centraalbureau voor Schimmmycelium was suspended in 300 μl of lysis buffer and incubated
with shaking at 70 °C for 10 min. The final DNA extraction
volume was 120 μl of bidest water.
2.3. PCR amplification, sequencing and MLST analysis
Adapted from earlier genotyping studies [16–24], PCR
amplification with different primer pairs was attempted for five
isolates from each species (S. apiospermum and P. boydii) for
the following genes: actin (ACT), calmodulin (CAL, exon 3–4),
second largest subunit of RNA polymerase II gene (RPB2),
β-tubulin (BT2, exon 2–4), manganese superoxide dismutase
(SOD2) and elongation factor 1 alpha (EF1α). To optimise the
amplification of calmodulin in S. apiospermum and P. boydii
isolates, one primer pair was newly designed based on sequences
available from the NCBI website.
The PCR assay (25 μl) included 1 μl of fungal DNA extract,
1 μM of each gene-specific primer (Table 3, TIB MOLBIOL,
Berlin, Germany), 0.2 mMof each deoxynucleoside triphosphate
(Roche, Mannheim, Germany), 1× BioTherm™ PCR buffer
with 1.5 mM of MgCL2 (Rapidozym, Berlin, Germany) and
1.25 U BioTherm™ Taq DNA polymerase (Rapidozym, Berlin,
Germany). For SOD2 a Pfu DNA polymerase and 1× Pfu buffer
with 2 mM ofMgSO4 (Fermentas, St. Leon-Rot, Germany) were
used for the PCR reaction.
The amplification for all targeted genes was performed in a
T1-Thermocycler (Biometra, Göttingen, Germany) as follows:
5 min of initial denaturation at 95 °C, followed by 35 cycles at
95 °C for 30 s, gene-specific annealing temperature for 30 s
(Table 3) and 72 °C for 1 min (for RPB2 the annealing time was
2.5 min). The final extension step was 7 min at 72 °C. The
amplification products were electrophoretically resolved on a
1.4% agarose TBE gel (0.089 M Tris base, 0.089 M boric acid
and 0.002 M EDTA) including GelRed™ (0.83×, Biotium,
Hayward, CA, USA) and visualised by UV transillumination
(BioDocAnalyze, Biometra, Göttingen, Germany). The products
were purified using the QIAquick PCR purification kit (Qiagen,
Hilden, Germany). For the sequencing of both strands the
amplification primers were used. Sequencing was performed
according to the BigDye® Termination v3.1 Cycle sequencing
kit, and the reactions were run on the ABI Prism 3130 genetic
analyzer (Applied Biosystems, Darmstadt, Germany). Sequencing
analysis was performed using the SeqMan pro (Lasergene
DNASTAR version 8.1.5) and the BioEdit sequence Alignment
Editor (version 7.0.9.0). The sequences were trimmed; starting
and endpoints are defined in Table 4. Each variable sequence
was classified as a unique allele type. The combination of alleles at
each locus defined the sequence type (#ST). All alleles of each
locus were BLAST searched against the NCBI GenBank to prove
the specificity of the amplified product.
The data was submitted to the MLST database for pathogenic
fungi (http://mlst.mycologylab.org/).le; f — female; CFTR— cystic ﬁbrosis transmembrane conductance regulator;
— Brandenburg; HH— Hamburg; LS— Lower Saxony; NW— North Rhine-
elcultures.
Table 2
List of S. apiospermum isolates showing the allele types of ITS and the five MLST loci and sequence types (STs).
Patient no.
Age§
[y]
Sex CFTR  genotype
CF center
(federal
state)
Isolation 
year/month
Source RKI no. ITS ACT CAL RPB2 BT2 SOD2 ST
29 21 m Unknown F (LS) 2009/08 Sputum 09-0593.01 S1 S1 S1 S1 S1 S1 #S1
39 28 m delF508/delF508 A (BE) 2010/02 Sputum 10-0177.01 S1 S1 S1 S1 S1 S1 #S1
32 21 f Unknown F (LS) 2009/11 Sputum 09-0800.01 S1 S1 S1 S1 S1 S9 #S2
9 12 f Unknown B (BE) 2002/01 Sputum 02-0098.01 S1 S1 S1 S1 S3 S1 #S3
16 19 f Unknown B (BE) 2008/12 n.d. 08-0617.01 S1 S1 S1 S1 S5 S1 #S4
30 11 f delF508/R553X F (LS) 2009/09 Sputum 09-0652.01 S1 S1 S1 S3 S1 S4 #S5
F (LS) 2009/10 Sputum 09-0752.01 S1 S1 S1 S3 S1 S4 #S5
F (LS) 2009/12 Sputum 10-0038.01 S1 S1 S1 S3 S1 S4 #S5
F (LS) 2010/04* Sputum 10-0316.01 S1 S1 S1 S3 S1 S4 #S5
F (LS) 2010/04* Sputum 10-0317.01 S1 S1 S1 S3 S1 S4 #S5
34 13 m delF508/delF508 F (LS) 2009/12 Tracheal secretion 10-0037.01 S1 S1 S2 S1 S1 S3 #S6
F (LS) 2010/02 Sputum 10-0179.01 S1 S1 S2 S1 S1 S3 #S6
F (LS) 2010/06* Sputum 10-0416.01 S1 S2 S4 S1 S1 S1 #S21
F (LS) 2010/06* Sputum 10-0417.01 S1 S1 S2 S1 S1 S3 #S6
F (LS) 2010/09 Sputum 10-0595.01 S1 S1 S2 S1 S1 S3 #S6
45 20 f delF508/G542X F (LS) 2010/06 Sputum 10-0418.01 S1 S1 S2 S1 S1 S3 #S6
28 25 m delF508/delF508 F (LS) 2009/07 Sputum 09-0564.01 S1 S1 S2 S1 S1 S9 #S7
F (LS) 2009/11 Sputum 09-0751.01 S1 S2 S1 S1 S1 S10 #S14
F (LS) 2010/01 Sputum 10-0130.01 S1 S3 S1 S1 S1 S3 #S23
F (LS) 2010/08 Sputum 10-0593.01 S1 S2 S1 S1 S1 S10 #S14
44 14 f Unknown G (BW) 2010/04 Sputum 10-0257.01 S1 S1 S2 S1 S4 S3 #S8
11 18 f delF508/1525-1G>A I (BW) 2003/12 Sputum 03-0533.01 S3 S1 S3 S1 S6 S1 #S9
3 12 f Unknown C (BY) 2001/03 Sputum 01-0521.01 S1 S1 S4 S1 S7 S9 #S10
14 33 m Unknown I (BW) 2007/11 Sputum 07-0591.01 S1 S1 S4 S1 S1 S8 #S11
I (BW) 2008/11 Sputum 09-0021.01 S1 S1 S4 S1 S1 S8 #S11
25 22 f delF508/1717A B (BE) 2009/06* Sputum 09-0441.01 S2 S1 S4 S2 S5 S8 #S12
B (BE) 2009/06* Sputum 09-0442.01 S2 S1 S4 S2 S5 S8 #S12
A (BE) 2010/09 Sputum 10-0577.01 S2 S1 S4 S2 S5 S8 #S12
26 16 f Unknown L (BY) 2009/06 Sputum 09-0450.01 S1 S2 S1 S1 S1 S1 #S13
40 19 m delF508/delF508 A (BE) 2010/03 Sputum 10-0208.01 S1 S2 S1 S1 S1 S10 #S14
48 19 m delF508/delF508 F (LS) 2010/09 Sputum 10-0637.01 S1 S2 S1 S1 S1 S11 #S15
8 23 f Unknown B (BE) 2002/01 n.d. 02-0042.01 S1 S2 S1 S1 S3 S1 #S16
31 22 f Unknown F (LS) 2009/09 Sputum 09-0653.01 S1 S2 S1 S2 S1 S5 #S17
F (LS) 2009/09 Sputum 09-0654.01 S1 S2 S1 S2 S1 S5 #S17
7 29 f Unknown K (BY) 2001/03 Sputum 01-0718.01 S1 S2 S2 S1 S1 S3 #S18
K (BY) 2001/11 Sputum 01-0988.01 S1 S2 S2 S1 S1 S3 #S18
24 26 m Unknown B (BE) 2009/06 n.d. 09-0422.01 S1 S2 S2 S1 S7 S8 #S19
A (BE) 2009/09 Tracheal secretion 09-0706.01 S1 S2 S2 S1 S7 S8 #S19
21 6 m delF508/delF508 C (BY) 2009/02 Throat swab 09-0141.01 S3 S2 S3 S1 S6 S1 #S20
19 10 f R553X/R553X K (BY) 2008/10 Sputum 08-0633.01 S1 S3 S1 S1 S1 S1 #S22
K (BY) 2009/05 Sputum 09-0382.01 S1 S3 S1 S1 S1 S1 #S22
K (BY) 2009/08 Sputum 09-0539.01 S1 S3 S1 S1 S1 S1 #S22
K (BY) 2009/12 Sputum 09-0823.01 S1 S3 S1 S1 S1 S1 #S22
33 15 m delF508/R533X H (BW) 2009/11 Sputum 09-0821.01 S1 S3 S1 S1 S6 S8 #S24
43 15 f Unknown C (BY) 2010/04 Throat swab 10-0256.01 S1 S3 S1 S2 S6 S1 #S25
42 36 m delF508/delF508 F (LS) 2010/03 Sputum 10-0253.01 S1 S3 S2 S4 S1 S7 #S26
F (LS) 2010/06 Sputum 10-0471.01 S1 S3 S2 S4 S1 S7 #S26
4 19 f Unknown D (BW) 2001/05 Tracheal secretion 01-0602.01 S2 S3 S3 S2 S2 S5 #S27
D (BW) 2001/05 BAL 01-0603.01 S2 S3 S3 S2 S2 S5 #S27
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Patient no.
Age§
[y]
Sex CFTR genotype 
CF center
(federal
state)
Isolation 
year/month
Source RKI no. ITS ACT CAL RPB2 BT2 SOD2 ST
17 11 m delF508/delF508 B (BE) 2008/12 n.d. 08-0619.01 S1 S3 S3 S3 S1 S1 #S28
18 14 f delF508/2146delT B (BE) 2008/12 n.d. 08-0620.01 S1 S3 S4 S1 S2 S8 #S29
27 22 f delF508/delF508 E (BW) 2009/06* Sputum 09-0475.01 S2 S4 S1 S2 S6 S6 #S30
E (BW) 2009/06* Sputum 09-0475.02 S2 S4 S1 S2 S6 S6 #S30
E (BW) 2010/03 Sputum 10-0222.02 S2 S4 S1 S2 S6 S6 #S30
41 10 f delF508/delF508 F (LS) 2010/03 Palatine tonsil swab 10-0252.01 S2 S4 S3 S2 S2 S2 #S31
F (LS) 2010/09 Throat swab 10-0638.01 S2 S4 S3 S2 S2 S2 #S31
12 17 f delF508/delF508 F (LS) 2007/04 n.d. 07-0291.01 S2 S4 S3 S2 S2 S2 #S31
F (LS) 2008/01 BAL 08-0042.01 S2 S4 S3 S2 S2 S2 #S31
F (LS) 2008/04 Ethmoid 08-0196.01 S2 S4 S3 S2 S2 S2 #S31
F (LS) 2008/04 BAL 08-0197.01 S2 S4 S3 S2 S2 S2 #S31
22 33 m Unknown F (LS) 2009/02 Sputum 09-0169.01 S2 S4 S3 S2 S2 S2 #S31
F (LS) 2009/07 Sputum 09-0561.01 S2 S4 S3 S2 S2 S2 #S31
F (LS) 2009/07 Bronchus 09-0562.01 S2 S4 S3 S2 S2 S2 #S31
F (LS) 2009/11 BAL 09-0770.01 S2 S4 S3 S2 S2 S2 #S31
F (LS) 2009/11 Tissue 09-0789.01 S2 S4 S3 S2 S2 S2 #S31
15 36 f R347P/1078delT B (BE) 2008/03 Sputum 08-0118.01 S4 S5 S2 S2 S1 S1 #S32
B (BE) 2008/12 n.d. 08-0618.01 S4 S5 S2 S2 S1 S1 #S32
A (BE) 2010/07 Sputum 10-0054.01 S4 S5 S2 S2 S1 S1 #S32
CBS 100395 56 m None None 1993 BAL (HTX; Gemany) – S1 S2 S1 S1 S1 S3 #S33
CBS 100392 63 m None None 1993 Biopsy leg (Hungary) – S1 S3 S1 S5 S1 S12 #S34
CBS 117407T n.d. n.d. None None n.d. Keratitis (Brazil) – S2 S3 S1 S2 S8 S8 #S35
n.d.— no data; § — age at the date of first isolation of Scedosporium ssp.; m — male; f— female; CFTR— cystic fibrosis transmembrane conductance regulator;
⁎ and ~ — multiple isolates from the same sample; BW — Baden-Württemberg; BY — Bavaria; BE — Berlin; LS — Lower Saxony; and CBS — Centraalbureau
voor Schimmelcultures.
Table 2 (continued)
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More than one allele type was found for the ITS region of
the rDNA in both species; however, this was not included in the
MLST scheme because it did not provide new information on
the ST. For all isolates studied sequence data were obtained
for the five MLST loci ACT, CAL, RPB2, BT2 and SOD2.
Amplification or sequencing of EF1α failed with the primer
pairs studied. In total, for the five gene fragments 3375 bp were
analysed. The allele types of each gene locus were clearly
distinct between P. boydii and S. apiospermum.
In P. boydii 128 (3.8%) polymorphic sites were identified
among the five gene loci, whereas in S. apiospermum 92 (2.7%)
variable nucleotides were found (Table 4). In P. boydii analysis of
the loci ACT and RPB2 resulted in four alleles, of CAL and BT2 in
five and of SOD2 in six allele types. The variability of nucleotides
per locus ranged between 1.6% (CAL) and 14.6% (SOD2). In
comparison to P. boydii, twelve alleles were observed for the
SOD2 locus in S. apiospermum. For the other loci in S.
apiospermum four to eight alleles were identified. The lowest
variability of nucleotides was noted in CAL and ACT (1.4%), and
the widest one in SOD2 (6.3%). Altogether, eight different STs
were obtained by combining the five MLST loci in P. boydii
isolates from 14 patients, while 32 distinct STs were found in the
S. apiospermum isolates from 34 patients (Tables 1 and 2).
Twenty-seven out of 34 patients (79.4%) with S. apiospermumwere colonised by one or two individual STs. The ST #S1, #S6
and #S14 were shared by two patients, and the sequence type
#S31 was found in three patients. The three reference strains CBS
100392, CBS 100395 and CBS 117407T had an individual ST
(#S33 to #S35). In contrast to the high genetic diversity of S.
apiospermum isolates, only five out of 14 patients harbouring P.
boydii had a unique ST. The ST #P1 was identified in four, #P7 in
three and #P3 in two patients. The type strain CBS 101.22T had a
ST distinct from the other P. boydii isolates (#P9), but the ST of
CBS 418.73 (#P6) was identified also in patient 10. Interestingly,
in this patient two different STs (#P1 and #P6) were observed over
a nine year period. In five other patients (5, 13, 16, 35 and 38) a
unique ST was found in consecutive P. boydii isolates from a
period of up to ten years (Table 1). In patients colonised by S.
apiospermum it was only possible to compare isolates from a
period of up to three years. Twelve patients had a unique ST. Only
in patients 34 and 28 two and three different STs were found,
respectively (Table 2).
4. Discussion
While the life expectancy of patients with CF changed
dramatically within the last decade [25], also the spectrum of
microorganisms, including fungi, colonising the respiratory tract
became more diverse [7]. Therefore, to interpret the clinical
relevance of colonising fungi like Scedosporium, reproducible
Table 3
Primer oligonucleotides and annealing temperature for ITS and the MLST analysis.
Gene PCR product
size [bp]
PCR and sequence primer [5′-3′] Annealing
temp. [°C]
Ref.
ITS ~650 ITS5 — GGAAGTAAAAGTCGTAACAAGG 55 White et al. [15]
ITS4 — TCCTCCGCTTATTGATATGC
ACT ~1000 ACT-1 — TGGGACGATATGGAIAAIATCTTGCA 57 Hoffmann et al. [18]
ACT-4R — TCITCGTATTCTTGCTTIGAICTCCACAT
CAL ~650 CAL-FW — GACTATTCACTAACAACGCTGTG 55 This study
CAL-RW — GTCTAGTATAATCAAATCGTTAGAG
RPB2 ⁎ ~1300 RPB2-5F — GAYGAYMGWGATCAYTTYGG 55 Liu et al. [19]
RPB2-7R — CCCATRGCTTGYTTRCCCAT
BT2 ~650 BT2a — GGTAACCAAATCGGTGCTGCTTTC 58 Glass and Donaldson [16]
BT2b — ACCCTCAGTGTAGTGACCCTTGGC
SOD2 ~550 SOD2-F3 — TCACCACGATAAACACCACC 52 Unpublished, from W. Meyer
SOD2-R3 — CGTCGATACCCAAGAGAGGA
R: G or A; W: A or T; Y: C or T; and M: A or C.
Amplification/sequencing failed for: EF1α (EF-1 ATG GGT AAG GAR GAC AAG AC and EF-2 GGA RGT ACC AGT SAT CAT G; EF-1H ATG GGT AAG
GAR GAC AAG AC and EF-2T GGA AGT ACC AGT GAT CAT GTT [21]; and EF1-7(28) F CAT CGA GAA GTT CGA GAA GG and EF1-9(86) R TAC TTG
AAG GAA CCC TTA CC [22]).
⁎ For RPB2 sequencing additional primer RPB2-6F 5′-TGGGGKWTGGTYCCTGC-3′ RPB2-6R 5′-GCAGGCCARACCAWMCCCCA-3′ were used.
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developed including five loci turned out to be highly reproducible
and effective for the genotyping of P. boydii and S. apiospermum
sensu strictu. Again the results confirm the separation of the
two species as proposed by Gilgado et al. [23]. Primers for the
locus elongation factor 1α (EF1α) which is recommended for
molecular typing of S. aurantiacum and S. prolificans [17,24]
turned out to be ineffective in P. boydii and S. apiospermum. Due
to the high discriminatory power of the presented MLST scheme
it might be unnecessary to study this gene locus.
The present study confirms the high genetic diversity within the
species analysed as described before by a number of different
methods [3,10,26]. The distinction within S. apiospermum was
higher than the one within P. boydii. This seems to conflict
with a recent study on a comparable collective of CF patients
from France, where P. boydii is more frequently found as
S. apiospermum and therefore possibly a question of strains
studied [10]. Nevertheless, nearly all patients studied were
colonised by individual strains, five of which harboured two
or more of the P. boydii complex and S. prolificans (data not
shown). Mixed colonisation with different STs was apparently
stable since the STs were detected in sequential samples obtained
over a time span of up to nine years. Our results confirm a previous
study based on random amplification of polymorphic DNA
(RAPD) [3], which found a high genetic diversity inTable 4
Variability between the gene loci.
Locus Sequence
start [5′-3′]
Sequence
end [5′-3′]
Size [bp] P. boydii
Alleles [n] P
ACT ATCAAC GCGAAA 782 4
CAL TTAAAG TATCCC 579 5
RPB2 TAAGCT TCCCAA 1092 4
BT2 GACGAC CAGTCC 526 5
SOD2 TCTCCA GCGCGA 396 6
Sum/total 3375 1S. apiospermum colonising CF patients and documented the
persistence of strains over a period of thirteen months. These
authors found that different genotypes from the same patient were
usually closely related. In contrast, our MLST data indicate that
genotypes within the same patient can be clearly distinct and fungi
can permanently colonise the respiratory tract. It is open
for discussion whether an antifungal therapy could modify the
colonisation pattern. Distinct phenotypes regarding the resistance
pattern of the identical species can colonise the same patient [26].
The aim of longitudinal studies should be to correlate the MLST
data with clinical data, including the resistance pattern of isolates as
well as risk factors like diabetes mellitus, cortisone and antifungal
treatment. A substantial progress would be to analyse the in vitro
and in vivo resistance on a molecular level.
Considering the limited number of isolates, there was no
striking geographic clustering of genotypes. Nevertheless, three
patients with the same genotype of S. apiospermum (#S31) were
found in Lower Saxony, and two other patients were harbouring
an identical ST of P. boydii (#P1) in Hamburg. These patients
were treated at the same CF centre. Therefore, although to our
knowledge they have never met at the ambulatory, a transfer from
one patient to another or an exposure to the same source of fungi
cannot be excluded completely. To gain new insights on the
routes of infection, Scedosporium species have to be identified in
the surroundings of our patients. Our MLST scheme will allow anS. apiospermum
olymorphism [n] [%] Alleles [n] Polymorphism [n] [%]
18 2.3 5 11 1.4
9 1.6 4 8 1.4
19 1.7 5 17 1.6
24 4.6 8 31 5.9
58 14.6 12 25 6.3
28 3.8 92 2.7
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The prevalence of P. boydii and S. apiospermum in patients
from European countries varies. While in a set of clinical and
environmental strains fromAustria, Germany and theNetherlands
S. apiospermum was the most prevalent one, followed by
P. boydii [27], in Northern Spain and France P. boydii represents
the most prevalent species, followed by S. apiospermum [10,26].
It would be highly informative to analyse European isolates
from different countries with a unique molecular method. The
MLST scheme presented here will be a promising tool for further
epidemiological studies on fungi belonging to the P. boydii
complex in Europe and worldwide.
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